DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU. The ...

AZ and Daiichi Sankyo already claimed FDA approval for the HER2-low indication in the US last summer, adding to Enhertu's lengthening list of indications, which also includes second- and third ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer. I found community after my metastatic breast cancer diagnosis, ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

which types the Food and Drug Administration (FDA) has approved, how they compare with other treatment options, and their side effects. This drug works by combining the antibody trastuzumab with a ...

Biotech company Neurotech Pharmaceuticals this month received regulatory approval for its treatment of a a neurodegenerative ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.